Browse

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives

Cited 12 time in Web of Science Cited 10 time in Scopus
Authors
Kim, Toe-You; Han, Soe-Won; Bang, Yung-Jue
Issue Date
2007-11
Citation
Expert Review of Molecular Diagnostics, Vol.7 No.6, pp.821-836
Keywords
amplificationbiomarkerEGFRerlotinibFISHgefitinibmutationNSCLC
Abstract
EGF receptor (EGFR) activation has an important role in various steps of carcinogenesis and progression of non-small-cell lung cancer (NSCLC), implying that EGFR is a potential target for cancer therapy. Therefore, targeted treatments aimed at EGFR have been developed, of which tyrosine kinase inhibitors (TKls), gefitinib and erlotinib have shown activity in NSCLC. The unexpected findings of a lack of association between expression of EGFR, the target and efficacy of EGFR TKls and higher response in selective subgroups of patients were puzzling. Identification of somatic activating mutations in the EGFR tyrosine kinase domain solved the mystery and provided new insight. Several lines of study provided information on various molecular targets for EGFR TKl therapy. A target-based patient-selection strategy is expected to eventually lead to tailored therapy for lung cancer.
ISSN
1473-7159
URI
https://hdl.handle.net/10371/173072
DOI
https://doi.org/10.1586/14737159.7.6.821
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse